Skip to main content
Fig. 3 | Orphanet Journal of Rare Diseases

Fig. 3

From: Naproxcinod shows significant advantages over naproxen in the mdx model of Duchenne Muscular Dystrophy

Fig. 3

Naproxcinod improves skeletal muscle force in exercised mdx mice. a WBT5 and b WBT10 measured following 6 months of treatment in exercised mdx mice treated with vehicle (black bar), 20 mg/kg naproxen (grey bar), or 30 mg/kg naproxcinod (white bar). Data are presented as mean ± SEM. *represents the comparison between vehicle and treatment groups. # represents the comparison versus the naproxen-treated group. One-way ANOVA followed by Tukey post-hoc test. * and # P < 0.05, ***P < 0.001. N = 8-10 mice/group

Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172